Authors

Latest:

Dr Godara on the Selection of CAR T-Cell Therapies vs Bispecific Antibodies in R/R Multiple Myeloma

Amandeep Godara, MBBS, discusses important patient factors to consider when deciding between a CAR T-cell therapy vs bispecific antibody in relapsed/refractory multiple myeloma, and the importance of mitigating treatment-related toxicities associated with the administration of bispecific antibodies in this disease setting.

Ariel Perez Perez, MD

Latest:

Dr. Perez Perez on Results From a Retrospective Study of Polatuzumab Regimens in R/R LBCL

Ariel Perez Perez, MD, discusses key results and clinical implications from a retrospective study of polatuzumab-vedotin plus rituximab with or without bendamustine in relapsed/refractory large B-cell lymphomas.

Ann W. Silk, MD, MS

Latest:

Extending the Frontiers of Checkpoint Inhibition in Merkel Cell Carcinoma

In the treatment of unresectable or metastatic Merkel cell carcinoma, immune checkpoint inhibitors have activity and tolerability.

Matthew H. G. Katz, MD, CMQ, FACS, FASCO

Latest:

Dr. Katz on Neoadjuvant mFOLFIRINOX in Pancreatic Cancer

Matthew H. G. Katz, MD, CMQ, FACS, FASCO, discusses the efficacy of mFOLFIRINOX, a chemotherapy regimen consisting of oxaliplatin, irinotecan, leucovorin, and fluorouracil, prior to pancreatectomy in patients with borderline resectable pancreatic cancer.

Ashraf Badros, MBCHB

Latest:

Dr Badros on the Design of the AURIGA Study of Daratumumab/Lenalidomide in Newly Diagnosed Myeloma

Ashraf Z. Badros, MBCHB, discusses the design of the AURIGA trial of daratumumab plus lenalidomide in newly diagnosed myeloma following transplant.

Ryan Cassaday, MD

Latest:

Blinatumomab-Based Regimens Enhance and Refine the B-ALL Treatment Paradigm: With Ryan Cassaday, MD

Ryan Cassaday, MD, discussed insights from trials investigating blinatumomab in patients with B-ALL that were reported at the 2024 ASH Annual Meeting.

Paola Gehrig, MD

Latest:

Dr Gehrig on the Use of Genetic Testing in Endometrial Cancer

Paola Gehrig, MD, discusses the optimal use and timing of genetic testing in endometrial cancer.

Mayur Narkhede, MD

Latest:

Dr. Narkhede on Siltuximab for CRS and ICANS in Hematologic Malignancies

Mayur Narkhede, MD, discusses findings from a pre-planned interim analysis of a phase 2 trial investigating siltuximab for the treatment of cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome related to CAR T-cell therapy in adult patients with hematologic malignancies.

Thomas Bachelot, MD, PhD, Centre Leon Berard

Latest:

Unanswered Questions in HER2+ Breast Cancer

Considerations on the evolving landscape and ongoing unmet needs for patients with HER2+ breast cancer.

Richard J. Lin, MD, PhD

Latest:

Dr. Lin on Second-line CAR T-cell Therapy in Relapsed/Refractory DLBCL

Richard J. Lin, MD, PhD, discusses the manufacturing considerations that factor into the CAR T-cell decision-making process in diffuse large B-cell lymphoma, the importance of open communication between community and referral physicians, and how early referral leads to optimal patient outcomes with CAR T-cell therapy.

Rodney Pommier, MD

Latest:

Advice for Community Physicians Treating Patients with Neuroendocrine Tumor-Associated Carcinoid Syndrome

Drs Das, Pommier, and Zacks share their advice for community physicians treating patients who have neuroendocrine tumors with carcinoid syndrome and carcinoid heart disease.

Jason Porter, MD

Latest:

Dr Porter on the Potential Role for Taletrectinib in ROS1+ NSCLC

Jason Porter, MD, discusses the potential role of the next-generation TKI taletrectinib in patients with ROS1-positive non–small cell lung cancer, according to data from the phase 2 TRUST-II trial.

Vinayak G. Wagaskar, MBBS

Latest:

Dr. Wagaskar on Potential Explanations for the Obesity Paradox in Prostate Cancer

Vinayak G. Wagaskar, MBBS, discusses potential explanations for a paradoxical relationship between obesity and outcomes observed in prostate cancer.

Shahneen Sandhu, MD

Latest:

Dr. Sandhu on Findings with Niraparib in Metastatic Prostate Cancer

Shahneen Sandhu, MD, discusses findings with niraparib in metastatic prostate cancer from the phase 3 MAGNITUDE trial.

Tejas Patil, MD

Latest:

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

Drs Park and Patil delve into the evolving SCLC treatment paradigm by examining data from recent studies and focus on treatment developments for patients with ALK-positive NSCLC.

Tadeusz Robak, MD, PhD

Latest:

Dr. Roback on Subsequent Treatment Following Ibrutinib Discontinuation in CLL

Tadeusz Robak, MD, PhD, discusses subsequent treatment after discontinuation of ibrutinib on the phase 3 RESONATE-2 trial in patients with chronic lymphocytic leukemia.

Douglas Flora, MD, LSSBB, FACCC

Latest:

Assessing the Promise of AI in Oncology: Looking to the Future

In this final episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, discuss a roadmap of artificial intelligence (AI) advances in the next 5 to 10 years.

Matthew C. Ward, MD

Latest:

Dr. Ward on the Benefits of Delaying Salvage Therapy in Prostate Cancer

Matthew C. Ward, MD, discusses the benefits of delaying salvage therapy in prostate cancer.

Joseph Mikhael, MD, Translational Genomics Research Institute

Latest:

Impact of Clinical Trials on the Management of Multiple Myeloma

Continuing its discussion on clinical trials in multiple myeloma, the panel emphasizes the impact that data may have on the real-world treatment landscape.

Joseph Franses, MD, PhD

Latest:

Dr Franses on the Need for Prospective Data in Second-Line HCC and Beyond

Joseph Franses, MD, PhD, discusses the need for more prospective data in the second-line setting and beyond for patients with hepatocellular carcinoma.